Universe Pharmaceuticals Reports Q1/Q2 Revenue Drop
Ticker: UPC · Form: 6-K · Filed: Jul 3, 2025 · CIK: 1809616
| Field | Detail |
|---|---|
| Company | Universe Pharmaceuticals INC (UPC) |
| Form Type | 6-K |
| Filed Date | Jul 3, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: financial-results, revenue-decline, increased-loss
TL;DR
Universe Pharma's revenue down 29% to $9.2M, losses widening. Ouch.
AI Summary
Universe Pharmaceuticals INC reported financial results for the six months ended March 31, 2025. Revenues decreased by 29.0% to $9.2 million compared to $12.9 million in the same period of 2024. The company also experienced an increased loss from operations, rising 33.7% to $2.3 million, and a net loss of $3.3 million.
Why It Matters
The significant revenue decline and increased losses suggest potential challenges in the company's market position or operational efficiency, which could impact investor confidence.
Risk Assessment
Risk Level: medium — A significant revenue decrease and widening losses indicate potential financial distress or market challenges for the company.
Key Numbers
- $9.2M — Revenues (Six Months Ended March 31, 2025) (Represents a 29% decrease from the prior year period.)
- $2.3M — Loss from Operations (Six Months Ended March 31, 2025) (Increased by 33.7% compared to the prior year period.)
- $3.3M — Net Loss (Six Months Ended March 31, 2025) (Indicates a worsening financial performance.)
Key Players & Entities
- Universe Pharmaceuticals INC (company) — Filer of the report
- March 31, 2025 (date) — End of reporting period
- $9.2 million (dollar_amount) — Revenues for the six months ended March 31, 2025
- $12.9 million (dollar_amount) — Revenues for the six months ended March 31, 2024
- $2.3 million (dollar_amount) — Loss from operations for the six months ended March 31, 2025
- $1.7 million (dollar_amount) — Loss from operations for the six months ended March 31, 2024
- $3.3 million (dollar_amount) — Net loss for the six months ended March 31, 2025
FAQ
What caused the 29% decrease in revenues for Universe Pharmaceuticals INC for the six months ended March 31, 2025?
The filing does not provide specific reasons for the revenue decrease, only the reported figures of $9.2 million for 2025 compared to $12.9 million for 2024.
What is the total net loss reported by Universe Pharmaceuticals INC for the six months ended March 31, 2025?
The company reported a net loss of $3.3 million for the six months ended March 31, 2025.
How has the loss from operations changed for Universe Pharmaceuticals INC?
The loss from operations increased by 33.7%, from $1.7 million in the six months ended March 31, 2024, to $2.3 million in the six months ended March 31, 2025.
Does Universe Pharmaceuticals INC file annual reports under Form 20-F or Form 40-F?
Universe Pharmaceuticals INC indicated that it files annual reports under cover of Form 20-F.
What is the principal executive office address for Universe Pharmaceuticals INC?
The principal executive offices are located at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, China, 343100.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 3, 2025 regarding Universe Pharmaceuticals INC (UPC).